Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Syra Health Corp. Class A Common Stock (SYRA)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: SYRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.78% | Avg. Invested days 5 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.08M USD | Price to earnings Ratio - | 1Y Target Price 1.8 |
Price to earnings Ratio - | 1Y Target Price 1.8 | ||
Volume (30-day avg) 3217222 | Beta - | 52 Weeks Range 0.34 - 4.85 | Updated Date 01/14/2025 |
52 Weeks Range 0.34 - 4.85 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -54.9% | Operating Margin (TTM) -19.03% |
Management Effectiveness
Return on Assets (TTM) -75.54% | Return on Equity (TTM) -404.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6841126 | Price to Sales(TTM) 0.76 |
Enterprise Value 6841126 | Price to Sales(TTM) 0.76 | ||
Enterprise Value to Revenue 0.48 | Enterprise Value to EBITDA - | Shares Outstanding 8973770 | Shares Floating 6489649 |
Shares Outstanding 8973770 | Shares Floating 6489649 | ||
Percent Insiders 17.04 | Percent Institutions 7.86 |
AI Summary
Syra Health Corp. Class A Common Stock: A Comprehensive Overview
Company Profile:
Detailed History and Background:
Syra Health Corp., formerly known as BioDelivery Sciences International, Inc., was founded in 2004 and went public in 2014. The company initially focused on developing and commercializing pain medications. However, in 2019, BioDelivery Sciences acquired Syra Health, a provider of specialty pharmacy services, and shifted its focus to this new area. The company subsequently changed its name to Syra Health Corp. in June 2020.
Core Business Areas:
Syra Health operates in two core business segments:
- Specialty Pharmacy Services: This segment provides customized medication management services to individuals with complex health needs, including patients with chronic conditions like HIV and hepatitis C. Syra offers comprehensive services such as medication dispensing, adherence monitoring, and patient education.
- Product Manufacturing and Licensing: Syra holds several patents for innovative drug delivery technologies. The company manufactures and licenses these technologies to pharmaceutical companies for the development of new medications.
Leadership and Corporate Structure:
- CEO: Sue Y. Duncan
- President and COO: Robert V. Geromini
- CFO: Jeffrey A. Martin
- General Counsel: Jeffrey R. Smith
- Executive Vice President, Chief Sales and Market Access Officer: Jennifer A. Davenport
- Executive Vice President, Chief Scientific Officer: David R. Westfall
The company is headquartered in Raleigh, North Carolina, and employs approximately 100 people.
Top Products and Market Share:
Top Products and Offerings:
- Specialty Pharmacy Services: Syra operates through a network of seven specialty pharmacies located across the United States. The company offers services for various therapeutic areas, including HIV, hepatitis C, oncology, and immunology.
- Product Manufacturing and Licensing: Syra's patented drug delivery technologies include BEMA, ONSET, and BEMA CORE. These technologies enable extended-release, controlled-release, and taste-masked formulations for various medications.
Market Share:
- Specialty Pharmacy Services: Syra's market share in the fragmented specialty pharmacy market is estimated to be less than 1%. However, the company is experiencing rapid growth, with revenue in this segment increasing from $29 million in 2021 to $48 million in 2022.
- Product Manufacturing and Licensing: The market share for individual products licensed with Syra's technologies varies. For example, the HIV drug Adzenys ER, developed with BEMA technology, has a market share of approximately 15%.
Product Performance and Market Reception:
Syra's specialty pharmacy services have received positive feedback from patients, with high satisfaction scores for medication adherence, personalized care, and communication. The company's product licensing partnerships have also been successful, with several pharmaceutical companies adopting its innovative drug delivery technologies.
Total Addressable Market:
The total addressable market for specialty pharmacy services in the United States is estimated to be over $150 billion. The market for extended-release and controlled-release drug delivery technologies is even larger, exceeding $250 billion globally.
Financial Performance:
Recent Financial Statements:
- Revenue: Syra's total revenue in 2022 was $62 million, up from $42 million in 2021.
- Net Income: The company reported a net loss of $23 million in 2022, compared to a loss of $20 million in 2021.
- Profit Margins: Syra's gross margin in 2022 was 42%, while its operating margin was -37%.
- Earnings per Share (EPS): The company's EPS for 2022 was -$0.55.
Year-over-Year Comparison:
Syra's revenue growth in 2022 was driven by the strong performance of its specialty pharmacy services segment. However, the company continued to report net losses due to investment expenses related to its growth initiatives.
Cash Flow and Balance Sheet:
- Cash Flow: Syra generated $33 million in operating cash flow in 2022.
- Balance Sheet: The company had $31 million in cash and equivalents and $21 million in debt as of December 31, 2022.
Dividends and Shareholder Returns:
Dividend History:
Syra Health Corp. has not paid any dividends since it went public.
Shareholder Returns:
The company's stock price has declined over the past year, resulting in negative shareholder returns. However, Syra's long-term growth potential could generate positive returns for investors in the future.
Growth Trajectory:
Historical Growth:
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Carmel, IN, United States | ||
IPO Launch date 2023-09-29 | Co-Founder, CEO & Director Dr. Deepika Vuppalanchi Ph.D. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 78 | Website https://www.syrahealth.com |
Full time employees 78 | Website https://www.syrahealth.com | ||
Syra Health Corp., a healthcare services company, provides solutions in behavioral and mental health, population health, digital health, health education, and healthcare workforce in the United States. The company Syrenity, behavioral and mental health application that identifies and prevents the progression of negative factors that can influence individuals' mental health, by offering targeted assignments, education, monitoring symptoms, and providing interventions; digital health products, such as SyraBot that automates manual tasks to streamline healthcare professional care, aiding patients in identifying health warning signs, encouraging therapy and medical regimens, and space for patients to share personal information; and CarePlus, a customizable templates, e-prescribing, laboratory integration, and patient portal access. It offers analytics as a service which includes data collection, traditional to advanced analytics, predictive analytics, risk stratification, intervention analytics, spatial analytics gap analysis, analytics workforce public policy, and research; epidemiology, and health equity analytics solutions. In addition, the company offers medical communications, patient education, and healthcare training; and recruits nurses and allied health professionals for long-term fixed contract positions at hospitals and healthcare facilities. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.